Thus, incorporating a patient's individual biodistribution data, not only based on visual evaluation of tumor load and/or serum PSA measurement, but additionally on kidney and salivary gland uptake in diagnostic PSMA PET imaging before therapy or even by performing pre-therapeutic dosimetry seems rational for individual therapy planning to further optimize the efficacy of PSMA-targeted radionuclide therapy. The gene discussed is FOLH1; the disease is neoplasm.